action revis forecast taisho lower target price
potenti return maintain neutral
invest overview compani largest presenc
domest self-med over-the-counter market taisho unavoid feel
impact over-the-counter market weak center drink product build
platform oversea market acquisit bristol-my
squibb subsidiari vietnames compani duoc hau giang
southeast asia cicsa mexico recent purchas
french compani upsa think yet contribut profit
due impact goodwil amort rais sale
forecast reflect consolid duoc hau giang
acquisit upsa lower op due acquisition-rel
cost see littl potenti alpha sinc taisho typic low-growth high-
catalysts/risk greater effort encourag use over-the-counter product
japan way curb drug cost would posit catalyst taisho
share key neg catalyst would earn slump caus
failur escap drag domest over-the-counter weak taisho
lead sponsor rugbi world begin septemb
benefit greater exposur lipovitan could benefit
strong perform japanes team
valuat continu base target price ep
estim prev histor one year averag
month forward price-to-earnings
valuat metric
chang tp
number share mn
price month
price rel chart measur perform
topix close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
price aug upsid rate neutral target price analyst fumiyoshi sakai
profit tax
issuanc retir stock
net chang cash
number share mn
profit tax
cash equival
periarthr myalgia condit
type diabet
compani mention price
